Holen Sie sich die Stockscreener-App
121.48
3.20%
-4.02
Vorhandelsmarkt:
122.31
0.83
+0.68%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$125.50
Offen:
$125.635
24-Stunden-Volumen:
10.14M
Relative Volume:
1.59
Marktkapitalisierung:
$150.83B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
16.53
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-5.82%
1M Leistung:
-7.50%
6M Leistung:
+0.12%
1J Leistung:
+10.35%
1-Tages-Spanne:
$121.39
$125.64
1-Wochen-Bereich:
$121.39
$131.66
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.48 | 150.83B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,136.37 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.49 | 574.10B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.95 | 397.44B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.09 | 294.13B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.12 | 282.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. $GILD Shares Acquired by LPL Financial LLC - MarketBeat
Cerity Partners LLC Buys 19,673 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development - Insider Monkey
Gilead Sciences Inc (GILD) Shares Fall 3.2% -- What GF Score of 76 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Down by 3.12% on Jun 10: What Investors Need To Know - TradingKey
Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Yahoo Finance
Deutsche Bank AG Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BLI Banque de Luxembourg Investments - MarketBeat
4th Circ. Revives Ex-Gilead Worker's Defamation Suit - Law360
What I Wish I Knew About Hepatitis B: Personal Journeys Out of Asia - Gilead Sciences
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance
Gilead And Merck End Trodelvy-Keytruda Lung Cancer TrialGilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga
Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive
Ex-Gilead Worker Lands New Shot at Defamation Suit Over Firing - Bloomberg Law News
Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals - Fierce Pharma
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $165 - Moomoo
Cantor Fitzgerald reiterates Gilead stock rating on HIV trial data By Investing.com - Investing.com South Africa
Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma Letter
WINTON GROUP Ltd Sells 56,799 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Franklin Resources Inc. Sells 169,087 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review
Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group
Merck (MRK) and Gilead Sciences (GILD) Achieve Key Trial Milesto - GuruFocus
Merck, Gilead share positive phase 3 results from combination HIV pill - Seeking Alpha
Gilead and Merck’s Once-Weekly HIV Combo Pill Works in Trials - Bloomberg
Merck and Gilead discontinue lung cancer drug trial By Investing.com - Investing.com South Africa
Gilead and Merck’s once-weekly HIV pill meets trial goals - Investing.com
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study - Lelezard
Merck and Gilead discontinue lung cancer drug trial - Investing.com
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Business Wire
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - Yahoo Finance
Assessing Gilead Sciences (GILD) Valuation As Livdelzi Phase 3 PBC Results Shape Growth Expectations - simplywall.st
RBC Capital reiterates Gilead Sciences stock rating at Sector Perform By Investing.com - Investing.com South Africa
Gilead Sciences, Inc. $GILD Shares Acquired by O Shaughnessy Asset Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Erste Asset Management GmbH - MarketBeat
Clearbridge Investments LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Raised by Brandywine Global Investment Management LLC - MarketBeat
Is Gilead Sciences (GILD) a Good Stock to Buy? - HarianBasis.co
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
Gilead Sciences, Inc. $GILD Shares Purchased by ING Groep NV - MarketBeat
Los Angeles Capital Management LLC Sells 676,504 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Capital World Investors Has $5.26 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Capital Research Global Investors - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):